智通财经APP讯，微创脑科学(02172)公布2025年中期业绩，收入约3.83亿元，同比减少6.2%;公司权益股东应占溢利9292.3万元，同比减少35.25%;每股盈利0.16元。
于报告期内，该集团的国际业务延续强劲增长态势，海外收入达4710万元，较上年同期增长67.4%，且国际业务分部利润实现高速增长。其中，该集团在亚太地区、欧洲、中东和非洲地区(EMEA地区)、北美地区及拉美地区的销售收入均实现不同程度的快速增长。
截至报告期末，该集团共有8款产品实现出海，累计在34个海外国家或地区实现商业化，涵盖9个神经介入手术量排名全球前十的国家。集团于海外不同国家或地区共斩获9项产品注册证，为海外收入规模化增长夯实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.